# RAG System Evaluation Report

**Total Queries:** 50
**Agent Execution Time:** 1942.34 seconds (recalculated)

## Retrieval Metrics
- **Hit Rate@5:** 0.08
- **Mean Reciprocal Rank (MRR):** 0.07
- **nDCG@5:** 0.06

## Query Breakdown
### q_synth_1: What is the diagnostic yield of limited BRCA1/2 analysis compared to multigene panel testing for pathogenic BRCA1/2 mutations in patients at risk for hereditary breast cancer?

**Expected ID:** `dbfc271d` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 95d46aee, PMID_41875782, PMID_42462279, NCT03211611, PMID_42464142, NCT07197723, PMID_42471715, NCT04499534, b831c5dc, PMID_41693691, NCT03286842, 003feb36, bf1440c6, 5361d773, 115b3720, dcc4f694, e7943154, c9293393, 0d658320, PMID_42224954, cc0de4c7, de1ba106, 8fbc61e9, NCT04367675, bb440c4f, e7b3a20c, PMID_41520277, PMID_42437126

#### Generated Answer

> Based on the provided context, here is what can be concluded:

* An individual with a known deleterious BRCA1/2 mutation in a close family member who does not undergo gene testing should be followed according to the same screening/management guidelines as a carrier of a BRCA1/2 mutation [NCCN 95d46aee].
* Monoallelic pathogenic BRCA1/2 variants may act as low-penetrance susceptibility factors in pediatric and AYA CNS tumors rather than as primary oncogenic drivers [PubMed PMID_42462279].
* The awareness program effectively enhanced at-risk women's understanding and attitudes toward BRCA1/2 genetic testing, supporting its value as an educational strategy for at-risk populations [PubMed PMID_41875782].
* Rare germline BRCA1/2 variants were identified in 4.6% of pediatric, adolescent, and young adult (AYA) patients with primary CNS tumors [PubMed PMID_42462279].
* Pathogenic BRCA1/2 variants were identified in 14.35% of unselected Vietnamese patients with breast, ovarian, prostate, or pancreatic cancer [PubMed PMID_42464142].

Note: These statements are based solely on the provided context and do not constitute medical advice.

---

### q_synth_2: What are the characteristics of Li-Fraumeni syndrome, specifically the prevalence and diversity of constitutional TP53 gene mutations among affected families?

**Expected ID:** `38896f45` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT05631886, b8b45b27, NCT07008638, NCT07419893, 76ebb951, 04267766, c3c80ae5, PMID_42437265, PMID_42376199, b6cc406f, 6764dc4f, NCT05528354, 20c3400b, d4810e2f, 8fd52fea, 29061ee1, 54511d9d, d448967a, 32ee86e9, 8e56309f, NCT07511062, ba5941bd, PMID_42163716, PMID_41972336, PMID_42466845, PMID_41593906, PMID_42037246, PMID_41666291

#### Generated Answer

> Here's what I've extracted from the provided context blocks regarding TP53:

* The TP53 gene, also known as p53, is located in the cell nucleus and binds directly to DNA [NCCN b8b45b27].
* Germline mutations in the TP53 gene have been observed in over 50% (and in over 70% in some studies) of families with Li-Fraumeni syndrome [MS-8].
* The primary endpoint of a Phase I/II clinical trial is to define safety/tolerability and preliminary efficacy profile for the treatment of newly-diagnosed TP53-mutated acute myeloid leukemia (TP53m AML) [ClinicalTrials.gov NCT07008638].
* Germline genetic testing of the TP53 gene detected TP53 mutations in at least 50% of families with Li-Fraumeni syndrome [NCCN 76ebb951].
* In a study of patients with early-onset breast cancer, TP53 mutations were found in approximately 8% of patients who did not meet traditional LFS criteria for testing [NCCN 04267766].
* Deleterious TP53 mutations were identified in 75% of patients with a family history of at least 2 LFS-associated tumors [NCCN 04267766].

I hope this helps!

---

### q_synth_3: What is the recommended timing for performing breast self-examination (BSE) for premenopausal women?

**Expected ID:** `257a7d69` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_42436446, PMID_41546558, PMID_42392264, NCT06371508, NCT07692464, aeb2acb1, fb2277b7, NCT01271673, NCT05960643, aa7b23d7, NCT07348744, PMID_42450991, 73b42022, b2819ddd, ef43315b, d6421c77, 8bb80220, 017f67d3, c0f17ef0, acbdbb5d, 1deaedae, 275f4386, 22fc9f12, b9a35832, PMID_42446397, PMID_42173439, PMID_42386721, PMID_42371320

#### Generated Answer

> Based on the provided context blocks, here are some claims or metrics related to breast self-examination (BSE):

1. Effectiveness of hands-on BSE training:
Hands-on BSE training significantly increased breast cancer knowledge and reduced perceived barriers among female university students [PubMed PMID_42436446].
2. Process of adopting and maintaining BSE:
The Transtheoretical Model (TTM) can be used to understand women's behavior change related to BSE, highlighting the importance of self-efficacy, susceptibility perceptions, and health-motivation [PubMed PMID_41546558].
3. Determinants of performing BSE in Omani women:
Self-efficacy, perceived susceptibility, and health-motivation were significant predictors of regular BSE practice among Omani women [PubMed PMID_42392264].
4. Effectiveness of breast cancer and BSE education on fear and BSE skills:
Breast cancer and BSE education can positively impact breast cancer fear and BSE skills in women [ClinicalTrials.gov NCT06371508].
5. Improvement in breast cancer awareness among illiterate women:
An educational intervention using visual materials can improve breast cancer awareness among illiterate women of reproductive age [ClinicalTrials.gov NCT07692464].

Remember to append the exact Source ID bracket to the end of each sentence, as shown in the example.

---

### q_synth_4: What is the recommended surveillance strategy for germline TP53 mutation carriers with Li-Fraumeni syndrome?

**Expected ID:** `f4fbd2e8` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT05778149, 6764dc4f, NCT07535840, c3c80ae5, 04267766, 33ca42b0, b1ec1e52, NCT06413992, d4810e2f, 8fd52fea, 32ee86e9, 8e56309f, 20c3400b, 54511d9d, d448967a, 29061ee1, PMID_42163716, 18ddcdff, b6cc406f, NCT07419893, PMID_42376199, NCT07511062, PMID_42466845, PMID_41972336, PMID_41589893, PMID_42037246, PMID_41593906, PMID_41666291

#### Generated Answer

> 175 Deleterious TP53 mutations were identified in 3 of 4 patients [NCCN 6764dc4f].

---

### q_synth_5: What are the reported cases of Peutz-Jeghers syndrome associated with breast cancer, ovarian sex cord tumor with annular tubules, and adenoma malignum?

**Expected ID:** `2f7d157e` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT06242457, NCT03806075, ca93598d, NCT06001476, NCT00811590, cce9c1d6, PMID_42335429, NCT03781050, 9f179411, PMID_42410002, PMID_42399437, 266df0de, PMID_42423930, 2ec115cd, PMID_42439066, 648ed0d2, d901911e, 0d70abc3, PMID_42419310, 51e2144e, beb9e809, 7ebaa739, 83df5764, 1e4f5481, 27cd5237, PMID_42419308, 8f75d194, PMID_41910454

#### Generated Answer

> Here are the extracted claims and metrics related to Peutz-Jeghers syndrome:

* The mutation rate of STK11 gene associated with gastrointestinal malignancies is high [ClinicalTrials.gov NCT03806075]
* The risk of cancer in familial Peutz-Jeghers syndrome is very high [NCCN ca93598d]
* The lifetime risk of pancreatic cancer for individuals with germline STK11 pathogenic variants is high, with estimates ranging from 5%-15% [NCCN cce9c1d6]
* The absolute risk of breast cancer for individuals with Peutz-Jeghers syndrome is 40-60% [NCCN cce9c1d6]
* The absolute risk of epithelial ovarian cancer for individuals with Peutz-Jeghers syndrome is >10% [NCCN cce9c1d6]
* The absolute risk of pancreatic cancer for individuals with Peutz-Jeghers syndrome is >15% [NCCN cce9c1d6]
* The absolute risk of other cancers for individuals with Peutz-Jeghers syndrome is unknown but may be high [NCCN cce9c1d6]

Note that these metrics are based on the provided context and may not reflect the entire body of evidence on Peutz-Jeghers syndrome.

---

### q_synth_6: What is the long-term risk of breast cancer associated with lobular neoplasia?

**Expected ID:** `980310d7` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_42176390, 03139a73, ccd2016c, 63ef8e10, 7d04348a, NCT07613151, 14066297, e751d6c3, 60313074, 1f0fe047, 98dda694, PMID_42014495, 82ccc5e7, 7f6f2652, PMID_42011085, PMID_42220308, PMID_41704167, PMID_41918273, NCT05960201, NCT07313033, NCT06666439, 24823764, 1ead3f13, b8839439, bcaf3ab3, PMID_42081023, PMID_42135547, NCT06744101

#### Generated Answer

> Lobular neoplasia was mentioned in the context [NCCN ccd2016c] as follows:

* A history of previous breast biopsies, especially those in which the pathology revealed atypical hyperplasia or lobular carcinoma in situ (LCIS), is associated with an increased risk for breast cancer.

---

### q_synth_7: What types of cancers are included in Lynch syndrome/hereditary non-polyposis colorectal cancer?

**Expected ID:** `733939c0` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT07360834, NCT07445828, PMID_42288229, 27565dbe, ff496b28, 4048aa4d, b6f78f03, 75f7be2d, c4330225, 8a429052, PMID_41460162, NCT07412197, PMID_42269807, 812ea602, e51c55ea, 6e9acd63, e046e767, af9dd639, PMID_42419314, 2efabdb4, 13a61b73, PMID_42341482, PMID_42383458, PMID_42419310, NCT00341575, 92f81d87, PMID_42419308, NCT00262171

#### Generated Answer

> Lynch syndrome is an inherited genetic predisposition that increases the risk of developing several types of cancer, particularly colon and rectal cancers (colorectal cancer), as well as cancer of the uterine lining (endometrial cancer) [ClinicalTrials.gov NCT07360834]. It affects around 1 in 400 people in Europe.

---

### q_synth_8: What are the histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry?

**Expected ID:** `78280732` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_42377119, 842b0a2d, eb2fadf4, 4d9a44aa, 8dd06e55, NCT03838406, 06336cb0, 8634f3d0, 496340c7, 0052ff75, 62cb53c7, 431cad1c, 2702ecbe, NCT02034916, NCT02222883, 0ecf0b3a, NCT06831747, PMID_41454916, cf6b72b7, ad5602dc, PMID_42116756, PMID_42235423, PMID_42259465, NCT01945775, 0a533cbb, PMID_42155200, PMID_42189063, PMID_42247992

#### Generated Answer

> Based on the provided context, here are the relevant claims or metrics extracted for the topic "BRCA":

1. Identifying new and effective therapeutic targets in breast cancer (BRCA) remains an urgent clinical need [PubMed PMID_42377119].
2. The transcription factor In BRCA is a potential therapeutic target [PubMed PMID_42377119].
3. BRCA testing criteria are met when there is a positive family history of BRCA1/BRCA2 mutation, Jewish relatives, or other BRCA-related criteria are met [NCCN 8dd06e55].
4. The best management of any cancer patient (including those with BRCA) is in a clinical trial, and participation is encouraged [NCCN eb2fadf4, NCCN 4d9a44aa].

Note: These claims or metrics are extracted from the provided context blocks, specifically the abstract, guidelines, and clinical trial information.

---

### q_synth_9: What is the survival rate of men with BRCA2 mutations who develop prostate cancer?

**Expected ID:** `50d7c284` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** d176a30c, 5361d773, 24830cf3, 95b0b10c, fae88eec, b8a3a8b3, NCT04499534, NCT00899145, bb440c4f, 7394e999, 2dadab8f, PMID_41621779, PMID_42127212, NCT00897455, 2fa830c9, db70acab, 4cbc1020, 9bde9635, e4233a56, PMID_41875782, PMID_42036279, NCT03495609, 115b3720, PMID_42238311, PMID_41823437, PMID_42433303, NCT04428736, PMID_42437126

#### Generated Answer

> Here are the claims and metrics related to BRCA2 extracted from the context:

* BRCA2 mutations have also been reported to have a higher risk for pancreatic cancer [NCCN d176a30c].
* An analysis of 490 families with BRCA1 or BRCA2 mutations showed an increased risk for ocular melanoma in BRCA2 carriers (RR = 99.4, 95% CI = 11.1359.8) [NCCN d176a30c].
* In an analysis of samples taken from patients with familial pancreatic cancer, BRCA2 mutations were detected in 17% of patient samples [NCCN fae88eec], [NCCN b8a3a8b3].
* Pancreatic cancer patients with Ashkenazi Jewish ancestry may have a greater likelihood of testing positive for a BRCA1 or BRCA2 mutation, with prevalence of detected mutations in this group ranging from 5.5% to 19%, with mutations being more common for BRCA2 [NCCN b8a3a8b3].
* In 211 Ashkenazi Jewish breast cancer patients with a family history of pancreatic cancer, 7.6% had a BRCA2 mutation [NCCN b8a3a8b3].

---

### q_synth_10: What is the family history criteria for considering genetic testing for prostate cancer patients?

**Expected ID:** `42d74d2e` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 2b51bf8d, 9e8bcd21, d0f763ce, NCT05428319, c95c1e6b, 3fc7c81e, 374750be, b4e0b736, 48eb29aa, b354aab9, 23d42d8f, 7d36882c, NCT02177526, PMID_42249833, PMID_41720694, a32ff58e, 8365c6ef, d20c0f23, b4fa9227, PMID_42187002, PMID_42304957, PMID_42252578, PMID_42359636, PMID_42454507, PMID_42397987, NCT01727284, NCT01743638, NCT03088202

#### Generated Answer

> Based on the provided context, prostate cancer is mentioned in the following claims:

* Approximately 11% of patients with prostate cancer and at least 1 additional primary cancer carry germline P/LP variants associated with increased cancer risk. [NCCN d0f763ce]
* Prostate cancer-related bullets include:
	+ Metastatic, intraductal/cribriform histology, or high- or very-high-risk (see NCCN Guidelines for Prostate Cancer) prostate cancer at any age [NCCN 2b51bf8d], [NCCN 9e8bcd21], [NCCN c95c1e6b], and [NCCN 3fc7c81e]
	+ Any NCCN risk group (see NCCN Guidelines for Prostate Cancer) with the following family history: Ashkenazi Jewish ancestry; or ≥2 close relatives with either breast or prostate cancer (any grade) at any age [NCCN 2b51bf8d], [NCCN 9e8bcd21], [NCCN c95c1e6b], and [NCCN 3fc7c81e]
	+ High-grade (Gleason score ≥7) or intraductal prostate cancer at any age [NCCN c95c1e6b] and [NCCN 3fc7c81e]

Note that these claims are based on the provided context and may not represent the entire scope of information related to prostate cancer.

---

### q_synth_11: What is the approximate reduction in breast cancer risk for women carrying a BRCA1/2 mutation after undergoing RRSO?

**Expected ID:** `a69b06d7` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 95d46aee, PMID_41875782, PMID_42462279, NCT03211611, PMID_42464142, NCT07197723, PMID_42471715, NCT04499534, b831c5dc, PMID_41693691, NCT03286842, 003feb36, bf1440c6, 5361d773, 115b3720, dcc4f694, e7943154, c9293393, 0d658320, PMID_42224954, cc0de4c7, de1ba106, 8fbc61e9, NCT04367675, bb440c4f, e7b3a20c, PMID_41520277, PMID_42437126

#### Generated Answer

> Based on the provided context blocks, the following claims or metrics related to BRCA1/2 can be extracted:

* Women at risk for breast cancer who do not undergo gene testing should be followed according to the same screening/management guidelines as a carrier of a BRCA1/2 mutation [NCCN 95d46aee].
* The awareness program effectively enhanced at-risk women's understanding and attitudes toward BRCA1/2 genetic testing, supporting its value as an educational strategy for at-risk populations [PubMed PMID_41875782].
* Monoallelic BRCA1/2 variants were identified in 4.6% of pediatric, adolescent, and young adult patients with primary central nervous system tumors [PubMed PMID_42462279].
* Pathogenic or likely pathogenic BRCA1/2 variants were found in 1.4% of the overall cohort of pediatric, adolescent, and young adult patients with primary central nervous system tumors [PubMed PMID_42462279].
* The rate of general practitioners having sufficient knowledge of the adequate management of patients with BRCA1 / 2 mutation was not reported [ClinicalTrials.gov NCT03211611].
* Pathogenic BRCA1/2 variants were identified in 14.35% of Vietnamese patients diagnosed with breast, ovarian, prostate, or pancreatic cancer [PubMed PMID_42464142].
* The mutation burden was highest in ovarian cancer and triple-negative breast cancer (TNBC) where BRCA1 variants predominated over BRCA2 [PubMed PMID_42464142].

Note: These claims or metrics are strictly based on the provided context blocks and may not represent the entire scope of research related to BRCA1/2.

---

### q_synth_12: What is the recommended screening/management approach for an individual from a family with a known deleterious BRCA1/2 mutation who tests negative for the familial mutation?

**Expected ID:** `95d46aee` | **Hit@5:** 1 | **MRR:** 1.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 95d46aee, PMID_41875782, PMID_42462279, NCT03211611, PMID_42464142, NCT07197723, PMID_42471715, NCT04499534, b831c5dc, PMID_41693691, NCT03286842, 003feb36, bf1440c6, 5361d773, 115b3720, dcc4f694, e7943154, c9293393, 0d658320, PMID_42224954, cc0de4c7, de1ba106, 8fbc61e9, NCT04367675, bb440c4f, e7b3a20c, PMID_41520277, PMID_42437126

#### Generated Answer

> Based on the provided context, I can extract the following claims and metrics:

* An individual with a known deleterious BRCA1/2 mutation in a close family member who does not undergo gene testing should be followed according to the same screening/management guidelines as a carrier of a BRCA1/2 mutation [NCCN 95d46aee].
* Knowledge scores regarding BRCA1/2 genetic testing increased significantly from 6.87 ± 2.95 at baseline to 12.74 ± 3.42 post-intervention (p < 0.001) [PubMed PMID_41875782].
* Attitude scores similarly improved from 5.40 ± 2.04-9.67 ± 2.44 (p < 0.001) [PubMed PMID_41875782].
* Rare germline BRCA1/2 variants were identified in 17 of 367 patients (4.6%) [PubMed PMID_42462279].
* Among them, 5 patients (1.4% of the overall cohort) carried pathogenic or likely pathogenic variants, whereas 12 patients (3.3%) carried variants of uncertain significance (VUSs) [PubMed PMID_42462279].
* The primary endpoint was to determine the rate of GP having sufficient knowledge of the adequate management of patients with BRCA1 / 2 mutation [ClinicalTrials.gov NCT03211611].
* Pathogenic BRCA1/2 variants were identified in 158 (14.35%) out of 1,101 Vietnamese patients diagnosed with breast, ovarian, prostate, or pancreatic cancer [PubMed PMID_42464142].

Please note that these claims and metrics are extracted from the provided context blocks and may not be a comprehensive summary of all information related to BRCA1/2.

---

### q_synth_13: What are some possible genetic predispositions or family history indicators for an individual's risk of developing thyroid cancer, diffuse gastric cancer, aggressive prostate cancer, or hamartomatous polyps of the GI tract?

**Expected ID:** `dcb3b7c0` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_pass`

**Retrieved Sources:** fc98b019, d0aa2012, 88ac3d91, 81226c96, e2207202, ed345fe4, 7cbc666c, 521c4bae, 30900271, da75ab9e, d73da539, d9d82fff, a4072119, 3dfa1d63, b9d6c136

#### Generated Answer

> Here's the answer based on the provided context blocks:

* Thyroid cancer: mentioned as one of the family history factors for further risk evaluation and genetic testing [NCCN fc98b019], [NCCN 88ac3d91], [NCCN e2207202], and [NCCN ed345fe4]
* Prostate cancer: mentioned as one of the family history factors for further risk evaluation and genetic testing [NCCN d0aa2012], [NCCN 81226c96], [NCCN e2207202], and [NCCN ed345fe4]; Gleason score ≥7 is specifically mentioned [NCCN d0aa2012]
* Gastric cancer: diffuse gastric cancer is mentioned as one of the family history factors for further risk evaluation and genetic testing [NCCN d0aa2012], [NCCN 81226c96], and [NCCN e2207202]; hamartomatous polyps of GI tract are also mentioned [NCCN fc98b019]
* Hamartomatous polyps: mentioned as one of the family history factors for further risk evaluation and genetic testing [NCCN fc98b019]

---

### q_synth_14: What standardized human pedigree nomenclature recommendations are available for genetic testing?

**Expected ID:** `5af8efdb` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 8f8a647b, 16e71962, 4a563150, c10bff20, 09baed84, 21effeb7, 5c5c7bb3, b19a4e96, f7955efc, 6b0b4b77, e8dbfb6b, 574fa1ba, f31f90c6, 6bb2e47b, dbe7507f

#### Generated Answer

> An expanded pedigree collected beginning with the health of the individual diagnosed with cancer and proceeding outward to include first-, second-, and third-degree relatives on both the maternal and paternal sides. [NCCN 8f8a647b]

Standardized pedigree nomenclature should be used. [NCCN 8f8a647b]

Unaffected family members, both living and deceased, are also included, as their histories also provide information about the magnitude of genetic risk. [NCCN 8f8a647b]

---

### q_synth_15: What is the role of BRCA2 gene in DNA interstrand cross-link repair?

**Expected ID:** `39947406` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** d176a30c, 5361d773, 24830cf3, 95b0b10c, fae88eec, b8a3a8b3, NCT04499534, NCT00899145, bb440c4f, 7394e999, 2dadab8f, PMID_41621779, PMID_42127212, NCT00897455, 2fa830c9, db70acab, 4cbc1020, 9bde9635, e4233a56, PMID_41875782, PMID_42036279, NCT03495609, 115b3720, PMID_42238311, PMID_41823437, PMID_42433303, NCT04428736, PMID_42437126

#### Generated Answer

> Based on the provided context blocks:

* BRCA2 mutations have also been reported to have a higher risk for pancreatic cancer [NCCN d176a30c].
* The BRCA2 gene, located on chromosome 13, is involved in repair of replication-mediated double-strand DNA breaks [NCCN 5361d773].
* In an analysis of samples taken from patients with familial pancreatic cancer, BRCA2 mutations were detected in 17% of patient samples [NCCN fae88eec].
* Pancreatic cancer patients with Ashkenazi Jewish ancestry may have a greater likelihood of testing positive for a BRCA1 or BRCA2 mutation, with prevalence of detected mutations in this group ranging from 5.5% to 19%, with mutations being more common for BRCA2 [NCCN b8a3a8b3].
* In 211 Ashkenazi Jewish breast cancer patients with a family history of pancreatic cancer, 7.6% had a BRCA2 mutation [NCCN b8a3a8b3].

---

### q_synth_16: What are the cancers associated with LFS, as mentioned in the guidelines?

**Expected ID:** `df307737` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT07032922, NCT04367246, NCT02950987, 131d27ef, b2f91fc8, 51b9c115, 96b51e8d, dfedce63, dc407db2, 81652036, 5d6c418e, e7399023, 3b09441a, 1a29a9a1, fae706a2, 9d065575, PMID_42142485, 03c010a1, 76fb7247, PMID_42284937, PMID_42190411, PMID_42276420, PMID_42389043, PMID_41797681, PMID_41903381, NCT01737255, PMID_42425668, NCT02985138

#### Generated Answer

> Li-Fraumeni syndrome (LFS) is a genetic disorder that increases the risk of cancer [ClinicalTrials.gov NCT07032922]. People who have LFS are 24 times more likely to develop cancer than those who do not [ClinicalTrials.gov NCT07032922]. The lifetime malignancy risk for patients with classical LFS is between 80-90%, with 21% of those cancers occurring by the age of 15 years [ClinicalTrials.gov NCT04367246].

---

### q_synth_17: What are the modified requirements for inclusion of women with breast or ovarian cancer, considering their Ashkenazi Jewish descent?

**Expected ID:** `abd8cc31` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_trials ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 3b6a4627, 2364a3f5, 13117653, da920da3, 2acdde2c, d425392a, c7d94a03, 934482d9, 51b7318d, 9b97e49b, e0b180d1, 58da4c26, PMID_42250735, NCT03667417, PMID_42341482, 058da9b2, 178a2cdd, PMID_42320249, 35212c20, NCT01821833, PMID_42433605, PMID_42385482, PMID_42217373, PMID_42161058, PMID_42142701, NCT00001898, NCT05512260, NCT03740984

#### Generated Answer

> Breast cancer [NCCN 3b6a4627] / Ovarian cancer [NCCN 3b6a4627]

Criteria for further genetic risk evaluation:

* A known mutation in a cancer susceptibility gene within the family [NCCN 2364a3f5]
* Early-age-onset breast cancer [NCCN 13117653, NCCN da920da3, NCCN 2acdde2c, NCCN d425392a]
* Triple negative (ER-, PR-, HER2-) breast cancer diagnosed ≤60 y [NCCN 2364a3f5, NCCN 13117653, NCCN da920da3, NCCN 2acdde2c, NCCN d425392a]
* Two breast cancer primaries c in a single individual [NCCN 2364a3f5, NCCN 13117653, NCCN da920da3, NCCN 2acdde2c, NCCN d425392a]
* Breast cancer at any age, and ≥1 close blood relative d with breast cancer ≤50 y [NCCN 2364a3f5, NCCN 13117653, NCCN da920da3, NCCN 2acdde2c, NCCN d425392a]
* Breast cancer at any age, and ≥1 close blood relative d with invasive ovarian e cancer at any age [NCCN 2364a3f5, NCCN 13117653, NCCN da920da3, NCCN 2acdde2c, NCCN d425392a]
* Breast cancer at any age, and ≥1 close blood relative d with pancreatic cancer at any age [NCCN 2364a3f5, NCCN 13117653, NCCN da920da3, NCCN 2acdde2c, NCCN d425392a]
* Pancreatic cancer at any age [NCCN 2364a3f5, NCCN 13117653, NCCN da920da3, NCCN 2acdde2c, NCCN d425392a]
* From a population at increased risk f [NCCN 2364a3f5, NCCN 13117653, NCCN da920da3, NCCN 2acdde2c, NCCN d425392a]

Male breast cancer: An individual of Ashkenazi Jewish descent with breast [NCCN da920da3]

---

### q_synth_18: Should I perform molecular genetic testing for hereditary breast/ovarian cancer syndrome on a patient who has received an allogeneic bone marrow transplant?

**Expected ID:** `f817922e` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** e30fcaa5, 2bd4c0f6, 2d77e91a, 3d835b7b, bd4ef9d6, NCT00595348, 51b7318d, 645d9774, 58da4c26, 035f1352, PMID_42419314, PMID_42383458, PMID_42443503, PMID_42341482, 8a7c4f11, 9079aeb5, 5318851c, 60e34986, c7d94a03, 8261c2ec, PMID_42464142, NCT03246841, NCT01167842, NCT01374685, NCT00001898, PMID_42135054, PMID_42437126, PMID_42457876

#### Generated Answer

> Based on the provided context, here are some claims and metrics related to hereditary breast ovarian cancer:

* Individuals from families with a known deleterious BRCA1/BRCA2 mutation should undergo genetic testing [NCCN e30fcaa5].
* Women with a personal history of breast cancer + one or more of the following criteria: diagnosed age 45 y, two breast primaries when first breast cancer diagnosis occurred age 50 y, diagnosed age 60 y with a triple negative breast cancer, or diagnosed at any age with 2 close blood relatives with breast cancer should undergo genetic testing [NCCN e30fcaa5].
* Women diagnosed with breast cancer + one or more of the following criteria: diagnosed age 45 y, two breast primaries when first breast cancer diagnosis occurred age 50 y, diagnosed age 60 y with a triple negative breast cancer, or diagnosed at any age with 2 close blood relatives with breast cancer should undergo genetic testing [NCCN 2bd4c0f6].
* Women with a family history of breast/ovarian cancer + one or more of the following criteria: diagnosed age 45 y, two breast primaries when first breast cancer diagnosis occurred age 50 y, diagnosed age 60 y with a triple negative breast cancer, or diagnosed at any age with 2 close blood relatives with breast cancer should undergo genetic testing [NCCN 2d77e91a].
* Women with a family history of breast/ovarian cancer + one or more of the following criteria: diagnosed age 45 y, two breast primaries when first breast cancer diagnosis occurred age 50 y, diagnosed age 60 y with a triple negative breast cancer, or diagnosed at any age with 2 close blood relatives with breast cancer should undergo genetic testing [NCCN 3d835b7b].
* Women with a family history of breast/ovarian cancer + one or more of the following criteria: diagnosed age 45 y, two breast primaries when first breast cancer diagnosis occurred age 50 y, diagnosed age 60 y with a triple negative breast cancer, or diagnosed at any age with 2 close blood relatives with breast cancer should undergo genetic testing [NCCN bd4ef9d6].
* To evaluate the prevalence of BRCA1/2 mutation of breast cancer patients with family history of breast/ovarian cancer [ClinicalTrials.gov NCT00595348].
* To evaluate the prevalence of BRCA1/2 mutation of breast cancer patients without family history, but high risk of hereditary cancer [ClinicalTrials.gov NCT00595348].
* To evaluate the prevalence of BRCA1/2 mutation of family member of BRCA1/2 mutation [ClinicalTrials.gov NCT00595348].
* To evaluate the prevalence of ovarian cancer of population of above 3 groups [ClinicalTrials.gov NCT00595348].

---

### q_synth_19: What are the guidelines for managing patients with cancer?

**Expected ID:** `43621f56` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 257c6a82, b01c8be0, 7b58ae2a, 1ca5db03, PMID_42416861, f9c110fa, e40b2b2a, 981e0c98, cba0b81e, b77ced20, PMID_42403667, 9b97e49b, f21fa5a0, dc77d7e6, b939b12c, NCT06995976, PMID_42441083, a7704733, NCT06383871, PMID_42388532, 35212c20, NCT04125524, NCT04414150, PMID_42302807, PMID_42465713, PMID_42413527, PMID_42379203, NCT06926972

#### Generated Answer

> Cancer developing in people who do not carry a high-risk mutation is referred to as sporadic cancer [NCCN 1ca5db03].

---

### q_synth_20: What are some cancers associated with Li-Fraumeni Syndrome?

**Expected ID:** `1449cc73` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** e2d26469, PMID_42417139, PMID_42463867, 339cf69b, a7dc6c62, PMID_42399724, bd539fda, 18277970, 509644d2, 5af24052, NCT04323774, PMID_42026177, PMID_42411914, PMID_42371298, c337fad4, 0ef2bb0c, b06ef7f3, ca6b6eb0, PMID_42419310, 33d57327, PMID_42413839, 489d6f54, 42ab5b40, 8f78333d

#### Generated Answer

> Li-Fraumeni Syndrome (LFS) is a rare hereditary cancer syndrome associated with germline TP53 gene mutations [NCCN e2d26469]. It has been estimated to be involved in only [PubMed PMID_42417139] individuals. LFS, a highly penetrant cancer syndrome associated with a high lifetime risk of cancer, is characterized by a wide spectrum of neoplasms occurring at a young age, including soft-tissue sarcomas, osteosarcomas, premenopausal breast cancer, acute leukemia, and cancer of the colon, adrenal cortex, and brain tumors [NCCN 339cf69b].

---

### q_synth_21: What is the percentage of breast cancer risk reduction in individuals with a BRCA2 mutation receiving tamoxifen compared to placebo?

**Expected ID:** `01d9d03d` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 7fe19aa9, 9d623046, 333a161b, b046a30d, d96e38d4, f438293b, 9bde4f87, 37592818, PMID_42032759, d576ad9e, c0ee63e2, c231fad8, PMID_40358767, b0a35599, f919adb3, 7f005d73, PMID_40705362, PMID_42433835, NCT00253539, c9daedc4, NCT07499999, PMID_41608012, PMID_41097794, NCT00381927

#### Generated Answer

> Based on the provided context, here are some extracted claims or metrics related to BRCA2 and tamoxifen:

* Tamoxifen did not significantly reduce the incidence of contralateral breast cancer in women with inherited mutations in BRCA1 and BRCA2 [NCCN 9d623046].
* The risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers was similar to that observed in the general population, regardless of tamoxifen use [NCCN b046a30d].
* Contralateral breast cancer incidence was not significantly affected by tamoxifen in women with inherited mutations in BRCA1 and BRCA2 [NCCN d96e38d4].

Note: The claims or metrics are based on the specific context provided and may not represent the entire body of evidence on this topic.

---

### q_synth_22: What is the recommendation for communicating reproductive risks to research participants identified through cancer panels, as per recent studies?

**Expected ID:** `b39271af` | **Hit@5:** 1 | **MRR:** 0.50

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT04579432, b39271af, 8ed58fed, d608aa0a, 154db91a, 20ac0e5b, 4c0d4af0, 1c793f8d, 674ba5bc, a92c44f2, 361b5a80, 77277f01, 99346cb1, 9416e809, 257a7d69, 36d6cd5a, NCT06346418, PMID_42323841, PMID_42393826, PMID_42391314, PMID_42434969, PMID_42423388, PMID_42464117, PMID_42328968, NCT00438594, NCT00438282, NCT00443638, PMID_42351362

#### Generated Answer

> According to the provided context [ClinicalTrials.gov NCT04579432], it is stated that "reproductive health and rights are essential for the health and survival of people, economic development and prosperity" [Source ID: ClinicalTrials.gov NCT04579432].

---

### q_synth_23: What is the prevalence of germline mutations in cancer genes among pancreatic cancer patients with a positive family history?

**Expected ID:** `683d51e2` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 69e07178, 17e62a20, 5eab90e7, NCT02750657, 7c6a2e8c, 92bb7b8e, aef10ef8, NCT05659914, 73904412, b1aed4a9, NCT05138302, 67016a26, d5a0bf0a, 6e7b3171, 72ee66b3, 4c04f645, 4e6d53ca, 928a0d3c, PMID_42165335, NCT03174574, PMID_42383254, PMID_42048949, NCT01188109, PMID_42288239, PMID_42208634, PMID_41742461, PMID_42322945, PMID_41823133

#### Generated Answer

> Based on the provided context, the following genes are mentioned as typically tested for pancreatic cancer risk:

* ATM [NCCN 69e07178]
* BRCA1 [NCCN 69e07178, NCCN 17e62a20, NCCN 5eab90e7]
* BRCA2 [NCCN 69e07178, NCCN 17e62a20, NCCN 5eab90e7]
* CDKN2A [NCCN 69e07178, NCCN 17e62a20, NCCN 5eab90e7]
* MLH1 [NCCN 69e07178, NCCN 17e62a20, NCCN 5eab90e7]
* MSH2 [NCCN 69e07178, NCCN 17e62a20, NCCN 5eab90e7]
* MSH6 [NCCN 69e07178, NCCN 17e62a20, NCCN 5eab90e7]
* EPCAM [NCCN 69e07178, NCCN 17e62a20, NCCN 5eab90e7]
* PALB2 [NCCN 69e07178, NCCN 17e62a20, NCCN 5eab90e7]
* STK11 [NCCN 69e07178, NCCN 17e62a20, NCCN 5eab90e7]
* TP53 [NCCN 69e07178, NCCN 17e62a20, NCCN 5eab90e7]

Note that these genes are mentioned as typically tested for pancreatic cancer risk in the context of hereditary cancer testing criteria.

---

### q_synth_24: What chemoprevention options are available for breast cancer patients with BRCA mutations?

**Expected ID:** `1f00f97d` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_42377119, 842b0a2d, eb2fadf4, 4d9a44aa, 8dd06e55, NCT03838406, 06336cb0, 8634f3d0, 496340c7, 0052ff75, 62cb53c7, 431cad1c, 2702ecbe, NCT02034916, NCT02222883, 0ecf0b3a, NCT06831747, PMID_41454916, cf6b72b7, ad5602dc, PMID_42116756, PMID_42235423, PMID_42259465, NCT01945775, 0a533cbb, PMID_42155200, PMID_42189063, PMID_42247992

#### Generated Answer

> Based on the provided context, here are some claims and metrics related to BRCA:

* Identifying new and effective therapeutic targets for breast cancer (BRCA) remains an urgent clinical need [PubMed PMID_42377119].
* The transcription factor In BRCA [PubMed PMID_42377119].

Note that these are not specific metrics or claims about BRCA, but rather general statements about the importance of finding new therapeutic targets for BRCA and a mention of a transcription factor in the context of BRCA.

If you're looking for specific information about BRCA mutation testing criteria, here is some relevant information:

* Positive for familial BRCA1/BRCA2 mutation [NCCN 842b0a2d]
* Negative for familial BRCA1/BRCA2 mutation [NCCN 842b0a2d]
* BRCA testing criteria met [NCCN 8dd06e55]

Let me know if you have any further questions or if there's anything else I can help with!

---

### q_synth_25: What is the mean age at diagnosis of ovarian cancer for BRCA1/2 carriers?

**Expected ID:** `7d6c3792` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_pass`

**Retrieved Sources:** 934482d9, ebfdd1db, 3fba1346, 7e49947e, 498072c9, 52956b16, 83d644e8, a0a861f0, NCT06640348, 4172efb1, PMID_41423932, 72d07063, ff285d9d, NCT03400306, 92bb7b8e, 7c6a2e8c, aef10ef8, PMID_41520277, NCT07663513, PMID_42318797, PMID_41841642, NCT06121401, NCT07407062, 35212c20, PMID_42400372, PMID_42308349, PMID_42294769, PMID_42092750

#### Generated Answer

> Here are the extracted claims and metrics related to ovarian cancer:

* Increased risks of cancers of the fallopian tube and primary peritoneal cancer are also observed in this population [NCCN ebfdd1db].
* About 15% of unselected individuals will have a germline BRCA1 or BRCA2 mutation when diagnosed with invasive ovarian cancer [42,83].
* The cumulative risk of ovarian cancer by 80 years of age was 44% for BRCA1 mutation carriers and 17% for BRCA2 mutation carriers [NCCN 7e49947e].
* BRCA1/2 carriers have an estimated 8% to 62% lifetime risk for ovarian cancer, depending on the population studied [78,54,79-83,133,134].
* Thirteen patients were diagnosed with ovarian cancer as a result of the screening protocol, with 5 of the 13 patients being diagnosed with early-stage cancer [NCCN 498072c9].
* The sensitivity, positive predictive value, and negative predictive value of the screening protocol for detecting ovarian cancer within 1 year were 94.7%, 10.8%, and 100%, respectively [NCCN 498072c9].

Note: These claims and metrics are strictly based on the provided context blocks and may not represent a comprehensive summary of ovarian cancer research or clinical guidelines.

---

### q_synth_26: What is the prevalence of BRCA1 and BRCA2 founder mutations among Ashkenazi women with ovarian cancer or early-onset breast cancer?

**Expected ID:** `edb0a78e` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT00899145, 83fc9abd, NCT00897455, bb440c4f, e7b3a20c, PMID_42462279, cc0de4c7, 24830cf3, de1ba106, NCT04499534, 637d3c57, 95b0b10c, 5361d773, PMID_42464142, 2dadab8f, NCT03495609, 7394e999, e4233a56, c69ed016, PMID_41875782, PMID_42238311, PMID_42471715, 115b3720, e7943154, PMID_42135054, PMID_41823437, PMID_42437126, NCT04428736

#### Generated Answer

> Here are the extracted claims and metrics related to BRCA1/BRCA2:

* The BRCA1 gene is located on chromosome 17 [NCCN e7b3a20c]
* The BRCA1 gene is believed to be involved in both DNA repair and the regulation of cell-cycle checkpoints in response to DNA damage [NCCN e7b3a20c]
* The molecular mechanism through which BRCA1 functions to preserve genomic stability remains unclear [NCCN e7b3a20c]
* The BRCA2 gene, located on chromosome 13, is involved in repair of replication-mediated double-strand DNA breaks [NCCN bb440c4f]
* Mutations in the BRCA1 or BRCA2 genes can be highly penetrant [NCCN e7b3a20c]
* The probability of cancer development in carriers of BRCA1 and BRCA2 mutations is variable, even within families [NCCN e7b3a20c]
* Rare germline BRCA1/2 variants were identified in 17 of 367 patients (4.6%) with primary CNS tumors [PubMed PMID_42462279]
* Among the 17 patients with rare germline BRCA1/2 variants, 5 carried pathogenic or likely pathogenic variants, and 12 carried variants of uncertain significance (VUSs) [PubMed PMID_42462279]

Note: The Source ID brackets are appended to each sentence as required.

---

### q_synth_27: What is the relationship between BRCA2 mutation carrier status and breast cancer risk?

**Expected ID:** `18720a7c` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** d176a30c, 5361d773, 24830cf3, 95b0b10c, fae88eec, b8a3a8b3, NCT04499534, NCT00899145, bb440c4f, 7394e999, 2dadab8f, PMID_41621779, PMID_42127212, NCT00897455, 2fa830c9, db70acab, 4cbc1020, 9bde9635, e4233a56, PMID_41875782, PMID_42036279, NCT03495609, 115b3720, PMID_42238311, PMID_41823437, PMID_42433303, NCT04428736, PMID_42437126

#### Generated Answer

> Here are the claims or metrics related to BRCA2:

* BRCA2 mutations have also been reported to have a higher risk for pancreatic cancer [NCCN d176a30c].
* In an analysis of samples taken from patients with familial pancreatic cancer, BRCA2 mutations were detected in 17% of patient samples [NCCN fae88eec].
* BRCA2 mutations were more common in Ashkenazi Jewish breast cancer patients with a family history of pancreatic cancer, with prevalence ranging from 5.5% to 19% [NCCN b8a3a8b3].
* An analysis of 490 families with BRCA1 or BRCA2 mutations showed an increased risk for ocular melanoma in BRCA2 carriers (RR = 99.4, 95% CI = 11.1359.8) [NCCN d176a30c].

Please note that these claims or metrics are extracted from the provided context blocks and are strictly related to BRCA2.

---

### q_synth_28: What are some studies that support the use of magnetic resonance imaging (MRI) for breast cancer screening in women with a hereditary risk of breast cancer?

**Expected ID:** `2c829549` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT05486520, PMID_42360310, e26a9706, 299e3fc5, NCT00639171, NCT05989022, 023b4085, 49213fb6, 364b4d5d, PMID_42119169, 9f51a2cf, 3147273c, de8cd95f, PMID_42184602, 29e6ebf8, 459d6460, ba32c2de, ad0a26c3, e1327b23, PMID_41934823, PMID_42361750, NCT02608281, a9f2cfe3, 7e7c8aba, NCT04340180, PMID_42441046, PMID_41725365, PMID_42082655

#### Generated Answer

> Based on the provided context, I found the following information related to breast cancer MRI:

* The study [PubMed PMID_42360310] investigated automated diagnosis of breast cancer using deep learning techniques applied to digital mammography and magnetic resonance images. It reported that the Res-Net model achieved the highest accuracy, sensitivity, and specificity of 90.89%, 90.93%, and 95.39%, respectively, in classifying MRI images into normal, benign, and malignant categories.
* The study [NCCN e26a9706] mentioned that breast MRI is preferred over mammography due to the theoretical risk of radiation exposure in pathogenic/likely pathogenic variant carriers.
* The study [ClinicalTrials.gov NCT00639171] investigated magnetic resonance spectroscopy (MRS) for breast cancer detection, which allows biochemical spectroscopic data to be obtained in vivo from user-defined regions-of-interest.
* The study [ClinicalTrials.gov NCT05989022] compared low-dose spiral breast CT with MRI in major indications of MRI for breast diagnostics.

Note that the context also mentions the importance of early detection and treatment outcomes in breast cancer, as well as the role of radiologists experienced in breast MRI in diagnostic accuracy.

---

### q_synth_29: What are some key references for understanding the roles of BRCA1 and BRCA2 in cancer?

**Expected ID:** `aef5ff30` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT00899145, 83fc9abd, NCT00897455, bb440c4f, e7b3a20c, PMID_42462279, cc0de4c7, 24830cf3, de1ba106, NCT04499534, 637d3c57, 95b0b10c, 5361d773, PMID_42464142, 2dadab8f, NCT03495609, 7394e999, e4233a56, c69ed016, PMID_41875782, PMID_42238311, PMID_42471715, 115b3720, e7943154, PMID_42135054, PMID_41823437, PMID_42437126, NCT04428736

#### Generated Answer

> Based on the provided context, here are some claims or metrics related to BRCA1 and BRCA2:

* The BRCA1 gene is located on chromosome 17 and is believed to be involved in both DNA repair and the regulation of cell-cycle checkpoints in response to DNA damage. [NCCN e7b3a20c]
* The BRCA2 gene, located on chromosome 13, is involved in repair of replication-mediated double-strand DNA breaks. [NCCN e7b3a20c], [NCCN bb440c4f]
* Mutations in the BRCA1 or BRCA2 genes can be highly penetrant (for definition, see Table 1). [NCCN e7b3a20c], [NCCN bb440c4f]
* The probability of cancer development in carriers of BRCA1 and BRCA2 mutations is variable, even within families. [NCCN e7b3a20c]
* Rare germline BRCA1/2 variants were identified in 17 of 367 patients (4.6%) with primary CNS tumors. [PubMed PMID_42462279]
* Among the 17 patients carrying rare germline BRCA1/2 variants, 5 patients (1.4% of the overall cohort) carried pathogenic or likely pathogenic variants, whereas 12 patients (3.3%) carried variants of uncertain significance (VUSs). [PubMed PMID_42462279]

Note that these claims and metrics are extracted from the provided context blocks, including clinical trials, guidelines, and a research study published in PubMed.

---

### q_synth_30: What is the term used to describe a graphic illustration of family history?

**Expected ID:** `31220ffc` | **Hit@5:** 0 | **MRR:** 0.17

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_pass`

**Retrieved Sources:** 8236332c, 734af748, bdb05e0b, e6e00306, 53c68a7d, 31220ffc, 26bb3eb2, 4506ce76, 50db81f5, 30b761fb, aff746de, b3c705a5, b4d0606e, bf55bbed, c81d4222, PMID_39315390, PMID_30198272, PMID_26783080, PMID_34039930, PMID_29460775, PMID_34178068, PMID_28866640, PMID_36200579

#### Generated Answer

> When represented in diagram form using standardized symbols and terminology, it is usually referred to as a [pedigree or family tree] [NCCN 8236332c].
A graphic illustration of [family history] [NCCN 734af748].
A graphic illustration of [family history] [NCCN bdb05e0b].
When represented in diagram form using standardized symbols and terminology, it is usually referred to as a [pedigree or family tree] [NCCN e6e00306].
A graphic illustration of [family history] [NCCN 53c68a7d].
[Family relationships within a family combined with the medical history of individual family members] when represented in diagram form using standardized symbols and terminology, it is usually referred to as a [pedigree or family tree] [NCCN 31220ffc].

---

### q_synth_31: What is the estimated positive predictive value of Classic LFS criteria for detecting germline TP53 mutations?

**Expected ID:** `8acec951` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT05631886, b8b45b27, NCT07008638, NCT07419893, 76ebb951, 04267766, c3c80ae5, PMID_42437265, PMID_42376199, b6cc406f, 6764dc4f, NCT05528354, 20c3400b, d4810e2f, 8fd52fea, 29061ee1, 54511d9d, d448967a, 32ee86e9, 8e56309f, NCT07511062, ba5941bd, PMID_42163716, PMID_41972336, PMID_42466845, PMID_41593906, PMID_42037246, PMID_41666291

#### Generated Answer

> Here's the extracted information related to TP53:

* The TP53 gene (i.e., p53) is located in the cell nucleus and binds directly to DNA [NCCN b8b45b27]. It has been called the 'guardian of the genome' and plays important roles in controlling the cell cycle and apoptosis.
* Germline mutations in the TP53 gene have been observed in over 50% (and in over 70% in some studies) of families [NCCN b8b45b27].
* A study found that at least one core cancer type, had germline TP53 mutations [NCCN 76ebb951].
* In a recent analysis of patients with early-onset breast cancer (age of diagnosis <30 years), 6 out of 28 patients (33%) were found to have TP53 mutations [NCCN 76ebb951].
* Another study found that approximately 5% of patients with BRCA1/BRCA2 mutation-negative early-onset breast cancer (age of diagnosis ≤35 years) had TP53 mutations [NCCN 04267766].
* Deleterious TP53 mutations were identified in 3 out of 4 patients (75%) with a family history of at least 2 LFS-associated tumors [NCCN 76ebb951].

Note that these claims and metrics are all related to the TP53 gene and its relevance to cancer.

---

### q_synth_32: What is the recommended approach to genetic testing for an Ashkenazi Jewish individual with no known familial mutation?

**Expected ID:** `85acd80a` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 0f1e0781, 4cfc35f1, ae7cee37, d32f4965, 1d87ae61, 4655007e, 0a772eaf, 05c514c1, bf026ba9, 05c1824a, 36a04996, 734af748, 7a5b35cc, 581671bf, 9c43e1b3

#### Generated Answer

> Based on the provided context blocks, here are the relevant claims or metrics extracted for the core medical condition/biomarker "Ashkenazi Jewish":

* The frequency of 187delAG and 5385insC variants in BRCA1 approximates 1 in 40 among the Ashkenazi Jewish population [NCCN d32f4965].
* The frequency of the 6174delT variant in BRCA2 approximates 1 in 40 among the Ashkenazi Jewish population [NCCN d32f4965].
* For individuals of Ashkenazi Jewish descent with no known familial BRCA1/2 pathogenic or likely pathogenic variants, one approach is to first test for the three known founder variants; if the tests are negative and if the individual's ancestry also included non-Ashkenazi ethnicity, comprehensive genetic testing should be considered [NCCN 4cfc35f1].

Note: These findings can be searched in PubMed and ClinicalTrials.gov using the terms "Ashkenazi Jewish" along with the extracted claims or metrics.

---

### q_synth_33: What are the criteria for diagnosing Cowden syndrome?

**Expected ID:** `eb3ead0e` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_42394463, PMID_42397496, 59d9951b, 3c4b075e, c3beb8dd, 02f5b5c1, NCT04094675, 79288bae, 519dc5be, 68239bec, 2b186f6f, f6baa9be, PMID_42410002, 9b0cfbb6, 903214c4, NCT00971789, 9743c506, 1597f9ce, NCT00600275, 97efa1d8, 84b7fd34, PMID_42328350, PMID_42106060, PMID_42086021, NCT07218575, PMID_41966075, PMID_42350754, NCT06805734

#### Generated Answer

> Cowden syndrome (CS) is a hereditary cancer predisposition syndrome characterized by macrocephaly, mucocutaneous lesions, and increased cancer risk in the breast, thyroid, endometrium, kidneys, and colon [PubMed PMID_42394463].

The incidence of Cowden syndrome has been reported to be 1 in 200,000 [NCCN 59d9951b], although it is likely to be underestimated due to difficulties associated with making a clinical diagnosis of the disease [NCCN c3beb8dd] [NCCN 02f5b5c1].

Cowden syndrome is an autosomal dominant disorder, and most cases are associated with germline mutations in the PTEN gene [NCCN c3beb8dd] [NCCN 02f5b5c1].

The estimated penetrance of PTEN mutation is high, at approximately 80% [NCCN c3beb8dd].

---

### q_synth_34: What is the approximate reduction in breast cancer risk achieved by bilateral risk reduction mastectomy in moderate- and high-risk women, as reported in studies with median follow-up periods of 13-14 years?

**Expected ID:** `6c4eca87` | **Hit@5:** 1 | **MRR:** 1.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 6c4eca87, ff3f0c58, c5ba5a41, f35170c9, cff9ee0d, 9c82991f, 5e53154f, 8409bfd0, 893e03b8, PMID_42126651, 8f27c200, PMID_42166900, 05484177, 6f449e1c, PMID_41586897, fb735224, PMID_41949865, 58e8e407, PMID_41366105, PMID_42305648, PMID_41637687, b0a35599

#### Generated Answer

> Based on the provided context blocks from NCCN, here are the extracted claims and metrics related to bilateral risk reduction mastectomy (RRM):

* Decreased the risk of developing breast cancer by at least 90% in moderate- and high-risk women and in known BRCA1/2 mutation carriers [NCCN 6c4eca87]
* Reduces the risk for breast cancer (RR, 0.11; 95% CI, 0.04-0.32) [NCCN c5ba5a41] and [NCCN 9c82991f]
* Not significantly associated with reduced all-cause mortality [NCCN c5ba5a41] and [NCCN 9c82991f]
* Provides a high degree of protection against breast cancer in women with a BRCA1/2 mutation [NCCN f35170c9]

Note that the exact Source ID brackets are appended to each sentence as requested.

---

### q_synth_35: What is the association between hereditary diffuse gastric cancer and lobular breast cancer?

**Expected ID:** `758f21de` | **Hit@5:** 1 | **MRR:** 0.20

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 7f6f2652, ea7a7af3, 73628ec2, 24c7fd70, 758f21de, 2e7776b8, 19d0a846, cc4a17ae, bee7aa6a, 95b02a6a, fe9b504e, 73b3fa8d, a2c2d68a, 3e83cfd3, 716551ca

#### Generated Answer

> Here are some key claims and metrics related to "hereditary diffuse gastric cancer":

* The cumulative risk of female lobular breast cancer by the age of 75 was estimated to be as high as 52% [NCCN ea7a7af3]
* Hereditary diffuse gastric cancer (HDGC) is a rare hereditary syndrome that is also associated with development of lobular breast cancer [NCCN 7f6f2652]
* Germline CDH1 mutations may be associated with lobular breast cancer in the absence of diffuse hereditary diffuse gastric cancer [JAMA 2007;297:2360-2372. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17545690.] [NCCN ea7a7af3]
* The incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families was studied, showing an increased risk of both cancers. [Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001;121:1348-1353. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11729114.] [NCCN 2e7776b8]
* The risk of breast cancer in women with germline CDH1 mutations was found to be high, with a cumulative incidence of breast cancer by age 75 estimated to be around 52%. [Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007;297:2360-2372. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17545690.]

---

### q_synth_36: What are the inherited p53 gene mutations in breast cancer, and what are their clinical characteristics?

**Expected ID:** `501eae70` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT04695223, PMID_42342465, PMID_42163716, acec251b, 03f2bfe2, 37d83128, b8b45b27, PMID_42297232, 0d0bd302, dafd779b, PMID_42107262, b7a0191a, NCT04976439, PMID_42320297, 801b5b0d, NCT06088030, e884aeae, NCT07419893, PMID_42214793, 18ddcdff, 33ca42b0, 8e56309f, PMID_42361739, 04267766, c3c80ae5, 6764dc4f, NCT07511062, PMID_42242586

#### Generated Answer

> The TP53 gene is the most frequently mutated gene in human cancers [PubMed PMID_42342465].

---

### q_synth_37: What are the studies that evaluated breast cancer screening using magnetic resonance imaging (MRI) and mammography for women at high familial risk of breast cancer?

**Expected ID:** `86c2ac42` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT03777852, 0002a833, e0b180d1, 9b97e49b, df787e06, ff8e54b7, PMID_42393830, 910bf204, PMID_42319344, 2acdde2c, d425392a, da920da3, PMID_42377119, 2364a3f5, 13117653, PMID_42421228, PMID_42390481, e28220aa, e36a5f2e, NCT05408676, a1da9987, cadfbfd2, PMID_42371677, NCT01110954, PMID_42337391, NCT05781633, PMID_42329179, NCT01522300

#### Generated Answer

> Based on the provided context blocks, here are some key claims and metrics related to breast cancer:

* Breast cancer is the most common type of cancer among women worldwide [ClinicalTrials.gov NCT03777852].
* In Brazil, breast cancer is second only to non-melanoma skin cancer [ClinicalTrials.gov NCT03777852].
* Women with breast reconstruction after a mastectomy due to cancer have a favorable evolution [ClinicalTrials.gov NCT03777852].

Additionally, the National Comprehensive Cancer Network (NCCN) has established guidelines for individuals at increased risk of developing breast cancer, including those with:

* A first- or second-degree relative with breast cancer diagnosed ≤45 y [NCCN 0002a833].
* A known mutation in a cancer susceptibility gene within the family [NCCN ff8e54b7].
* Early-age-onset breast cancer [NCCN ff8e54b7].
* Triple negative (ER-, PR-, HER2-) breast cancer diagnosed ≤60 y [NCCN ff8e54b7].
* Two breast cancer primaries in a single individual [NCCN ff8e54b7].
* Breast cancer at any age, and ≥1 close blood relative with breast cancer ≤50 y, or ≥1 close blood relative with invasive ovarian cancer at any age, or ≥2 close blood relatives with breast cancer and/or pancreatic cancer at any age, or From a population at increased risk [NCCN ff8e54b7].
* Male breast cancer [NCCN ff8e54b7].
* An individual of Ashkenazi Jewish descent with breast, ovarian, or pancreatic cancer [NCCN 9b97e49b].

Note that these claims and metrics are based on the provided context blocks and may not represent the entire scope of information related to breast cancer.

---

### q_synth_38: What is the effect of hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers?

**Expected ID:** `b6cecc08` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_fail`

**Retrieved Sources:** NCT03777852, 0002a833, e0b180d1, 9b97e49b, df787e06, ff8e54b7, PMID_42393830, 910bf204, PMID_42319344, 2acdde2c, d425392a, da920da3, PMID_42377119, 2364a3f5, 13117653, PMID_42421228, PMID_42390481, e28220aa, e36a5f2e, NCT05408676, a1da9987, cadfbfd2, PMID_42371677, NCT01110954, PMID_42337391, NCT05781633, PMID_42329179, NCT01522300

#### Generated Answer

> Based on the provided context, there are no specific claims or metrics related to breast cancer that can be extracted. The text primarily discusses the importance of breast reconstruction and its impact on body contour satisfaction, as well as the criteria for high-risk breast cancer patients. 

However, if you're looking for general information about breast cancer, some key points can be gathered:

* Breast cancer is the most common type of cancer among women worldwide [ClinicalTrials.gov NCT03777852]
* It brings stigma, loss of female identity and body contour, impact on sexuality and fertility, and inability to breastfeed [ClinicalTrials.gov NCT03777852]
* Breast reconstruction can restore shape and physical integrity [ClinicalTrials.gov NCT03777852]

Please note that these points are not specific claims or metrics related to breast cancer, but rather general information about the disease.

---

### q_synth_39: What is the estimated lifetime risk of developing breast cancer for carriers of ATM mutations?

**Expected ID:** `6ad6c21a` | **Hit@5:** 0 | **MRR:** 0.08

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** d3a506ad, 55556993, 71920151, e605fa34, 511d8111, NCT05010031, NCT06177171, 82738ac3, 5cd7ecc8, a8970c16, b1b5e6d5, 2718aacc, 6ad6c21a, b8ab9f5d, f985664e, 792fac4e, 0a5f09a5, NCT03009682, PMID_42092301, PMID_42419313, PMID_42092629, PMID_42172983, PMID_42401126, PMID_42155956, PMID_42119969, PMID_42176651, NCT05694715, NCT03962114

#### Generated Answer

> The context suggests that:

* ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations are present [NCCN d3a506ad] and [NCCN 55556993].
* The presence of ATM heterozygotes is associated with a 9-fold increased risk for early-onset breast cancer and frequent bilateral occurrence [NCCN e605fa34].
* ATM pathogenic or likely pathogenic variantss in the ATM gene may increase risk for breast cancer, with a cumulative lifetime risk for breast cancer by age 50 years of 6% and by age 80 years of 33% [NCCN 511d8111].
* An analysis of 82 Dutch patients with early-onset breast cancer showed that 8.5% (n = 7) of the patients had a detected ATM mutation [NCCN e605fa34].

Please note that these findings are based on the provided context and may not be an exhaustive summary of all available information on ATM mutations.

---

### q_synth_40: What is the distinction between sporadic cancer and cancer that occurs in people who carry a germline pathogenic or likely pathogenic variant?

**Expected ID:** `e9cc6f6e` | **Hit@5:** 0 | **MRR:** 0.14

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** e7ce0add, 4017186c, 1da6b401, becdc0ea, 17a86b1a, 311412b4, e9cc6f6e, d9429876, e2df5ad5, PMID_42055234, 63c17b53, b7b87bc2, PMID_42252839, a3f98b2b, 06928acf, 4d7af91f, 4970b7f3, PMID_42045809, PMID_42269538, PMID_42224635, PMID_42164324, PMID_42120995

#### Generated Answer

> According to the provided context, sporadic cancer refers to:

* Cancer occurring in people who do not have a germline [NCCN e7ce0add]
* Cancer developing in people who do not carry a high-risk pathogenic or likely pathogenic variant [NCCN 4017186c], [NCCN 1da6b401], [NCCN becdc0ea]
* Cancer occurring in individuals without a family history of cancer [NCCN e7ce0add], [NCCN 4017186c]

Note that the context also mentions that sporadic cancer can have two meanings, but it is primarily used to describe cancers occurring in people who do not carry a high-risk pathogenic or likely pathogenic variant.

There is no mention of a "Likely" Pathogenic variant in the provided context. The term "pathogenic" refers to a variant that confers increased susceptibility to cancer, and "likely pathogenic" is used interchangeably with "pathogenic".

---

### q_synth_41: What is the 10-year survival rate among PALB2 carriers with breast cancer?

**Expected ID:** `9252146a` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 09665d3a, e0a84f9f, 9f88aeb4, 957599fc, NCT06403904, 2a6e42fa, NCT04756765, f87c6a58, 68edfb76, eb8f4db7, NCT06783140, 7636b6f4, NCT06078787, 68b6fcb0, PMID_42431822, 28b9eae3, PMID_41954240, NCT05232006, 47e2b207, 05f6d6f5, PMID_42127212, 6e7b3171, PMID_42358519, PMID_42238311, PMID_41823437, 8a9b323e, PMID_42426004, PMID_42036279

#### Generated Answer

> Based on the provided context blocks, here are the answers to your question:

1. What is the estimated RR for female breast cancer associated with PALB2 pathogenic or likely pathogenic variants?
Answer: An analysis including 764 families with a known pathogenic or likely pathogenic PALB2 variant estimated an RR of 7.18 (95% CI, 5.82-8.85) [NCCN e0a84f9f].

2. What is the estimated lifetime risk of breast cancer associated with PALB2 pathogenic or likely pathogenic variants?
Answer: PALB2 pathogenic or likely pathogenic variant is associated with a 33% to 53% lifetime risk of breast cancer [NCCN 9f88aeb4, NCCN 957599fc].

3. What is the proportion of patients with breast cancer who harbor a PALB2 P/LP variant?
Answer: Studies of patients with breast cancer show that 0.4% to 3% harbor a PALB2 P/LP variant [NCCN 09665d3a, NCCN 957599fc].

4. What is the estimated RR for female breast cancer associated with PALB2 P/LP variants?
Answer: A meta-analysis of three studies estimated an RR of 5.3 (90% CI, 3.0-9.4) [NCCN 09665d3a, NCCN 957599fc].

Note: RR stands for relative risk, and CI stands for confidence interval.

---

### q_synth_42: What is the frequency of BRCA1 and BRCA2 mutations in male breast cancer cases from a population-based study?

**Expected ID:** `2ae78680` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_trials ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_42235864, NCT00597987, 83fc9abd, 8fbc61e9, e7b3a20c, cc0de4c7, 24830cf3, bb440c4f, de1ba106, 5361d773, PMID_42309254, 95b0b10c, 30d19d14, PMID_42329179, 2dadab8f, 637d3c57, NCT04499534, PMID_41467426, PMID_42026967, c69ed016, NCT04367675, df787e06, NCT03211611, 115b3720, PMID_42393830, PMID_41693691, NCT07197723, PMID_41520277

#### Generated Answer

> Lower expression of BRCA1 in cardiomyoblast alters the expression of apoptotic, inflammatory and metabolic pathway genes, and enhances catecholamine-induced hypertrophic response [PubMed PMID_42235864].

BRCA1 is located on chromosome 17 and is believed to be involved in both DNA repair and in the regulation of cell-cycle checkpoints in response to DNA damage [NCCN e7b3a20c].

Mutations in the BRCA1 gene can be highly penetrant, although the probability of cancer development in carriers of BRCA1 mutations is variable [NCCN cc0de4c7].

---

### q_synth_43: What is the frequency of BRCA mutations in Ashkenazi Jewish men with prostate cancer?

**Expected ID:** `8a421050` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_42377119, 842b0a2d, eb2fadf4, 4d9a44aa, 8dd06e55, NCT03838406, 06336cb0, 8634f3d0, 496340c7, 0052ff75, 62cb53c7, 431cad1c, 2702ecbe, NCT02034916, NCT02222883, 0ecf0b3a, NCT06831747, PMID_41454916, cf6b72b7, ad5602dc, PMID_42116756, PMID_42235423, PMID_42259465, NCT01945775, 0a533cbb, PMID_42155200, PMID_42189063, PMID_42247992

#### Generated Answer

> Based on the provided context, I can extract the following claims and metrics related to BRCA:

* Identifying new and effective therapeutic targets in breast cancer (BRCA) is an urgent clinical need [PubMed PMID_42377119].
* The transcription factor In BRCA is a potential therapeutic target [PubMed PMID_42377119].

Note that these are the only mentions of BRCA in the provided context. If you would like me to extract any specific information about BRCA-1/BRCA2 mutation testing or management, I can do so as well!

---

### q_synth_44: What is recommended for individuals who do not meet criteria for testing but are still considered at increased risk of familial breast cancer?

**Expected ID:** `696fcade` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT04058418, PMID_42068564, fb9255b8, PMID_42223121, d2d3c0cc, 5992c327, 8aaf5679, 428d18ed, 4f821a7e, 6a5d5008, 13a134e4, PMID_42297814, PMID_42252839, PMID_42033881, 3c75a7f3, 7f2e02bb, f69ce59c, 879af4cb, 32e94d9c, PMID_41991965, a1da9987, cadfbfd2, PMID_41846317, NCT03959267, NCT05392608, NCT02557776, NCT03495544, PMID_41321007

#### Generated Answer

> Familial breast cancer can be caused by co-pathogenic role of BRCA1 and OBSCN deletions [PubMed PMID_42068564]. 

The incidence of breast cancer is high among women, with a significant proportion of cases being familial [PubMed PMID_42068564]. Women with a family history of breast cancer have an elevated risk of developing the disease [PubMed PMID_42223121].

A series of analyses suggested that the co-occurrence of heterozygous deletions in BRCA1 and OBSCN was the main cause of breast cancer in this family [PubMed PMID_42068564]. 

The simultaneous association of 2 genes with the occurrence of breast cancer was discovered for the first time in this family, which could help guide disease prevention for families [PubMed PMID_42068564].

Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes have been identified in women with ovarian tumors, but not familial breast cancer [NCCN fb9255b8].

Whole-exome sequencing (WES) and bioinformatics analyses were used to identify potential driver genes, followed by Sanger sequencing for validation, which ultimately confirmed the pathogenic gene and the underlying mechanism in this family [PubMed PMID_42068564].

---

### q_synth_45: What are some examples of studies that used preimplantation genetic diagnosis for BRCA1/2 mutations?

**Expected ID:** `c427ee4f` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_trials ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 95d46aee, PMID_41875782, PMID_42462279, NCT03211611, PMID_42464142, NCT07197723, PMID_42471715, NCT04499534, b831c5dc, PMID_41693691, NCT03286842, 003feb36, bf1440c6, 5361d773, 115b3720, dcc4f694, e7943154, c9293393, 0d658320, PMID_42224954, cc0de4c7, de1ba106, 8fbc61e9, NCT04367675, bb440c4f, e7b3a20c, PMID_41520277, PMID_42437126

#### Generated Answer

> Based on the provided context blocks, here is what I found:

* An individual with a known deleterious BRCA1/2 mutation in a close family member who does not undergo gene testing should be followed according to the same screening/management guidelines as a carrier of a BRCA1/2 mutation [NCCN 95d46aee].
* Monoallelic BRCA1/2 variants may act as low-penetrance susceptibility factors in pediatric and AYA CNS tumors rather than as primary oncogenic drivers [PubMed PMID_42462279].
* The awareness program effectively enhanced at-risk women's understanding and attitudes toward BRCA1/2 genetic testing, supporting its value as an educational strategy for at-risk populations [PubMed PMID_41875782].
* Pathogenic or likely pathogenic BRCA1/2 variants were identified in 17 of 367 patients (4.6%) with primary CNS tumors [PubMed PMID_42462279].
* The rate of GP having sufficient knowledge of the adequate management of patients with BRCA1 / 2 mutation was determined to be [ClinicalTrials.gov NCT03211611].
* Pathogenic BRCA1/2 variants were identified in 14.35% (158 out of 1,101) of unselected Vietnamese patients diagnosed with breast, ovarian, prostate, or pancreatic cancer [PubMed PMID_42464142].

Please note that these claims are based on the provided context blocks and may not be exhaustive.

---

### q_synth_46: What is the recommended approach for genetic counseling when a patient has cancer and a family history of diffuse gastric cancer?

**Expected ID:** `c69d2317` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 24c7fd70, PMID_42311607, 2e7776b8, ea7a7af3, f232b26b, 47a82ed9, dc91ba7c, a4dc0066, 7ebd1c7b, PMID_42068022, c042ae4d, 19d0a846, 3cb457ea, 7f7c14a4, NCT00320515, 31ffbffe, c6e33c29, 53f457ff, PMID_42021123, PMID_42058264, NCT03890354, PMID_42311610, NCT02661945, PMID_42318089, NCT03208777, PMID_42247321, NCT01579071, PMID_41709439

#### Generated Answer

> Here are the extracted claims/metrics related to gastric cancer:

* WGA (White Globe Appearance) is a predictive marker for metachronous gastric cancers [NCCN 24c7fd70]
* The incidence of gastric cancer is significantly higher in CDH1 mutation carriers from hereditary diffuse gastric cancer families compared to the general population [NCCN Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001;121:1348-1353]
* Gastric cancer risk is increased in individuals with personal or family history of diffuse gastric cancer [NCCN]

Please note that these claims/metrics are based on the provided context blocks and may not be exhaustive.

---

### q_synth_47: What reproductive options should patients of reproductive age be advised on, considering pre-implantation genetic diagnosis?

**Expected ID:** `0bc9aa93` | **Hit@5:** 0 | **MRR:** 0.17

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** f783eeb2, 623b8e28, 2ad42c69, PMID_42415645, 5ac41d4f, 0bc9aa93, f2efe259, NCT05936749, 4033da5f, PMID_42233170, NCT02676479, PMID_41906365, NCT06023472, 57c07023, 38e399c1, 11acf7ef, 5aad71ae, c05e9f29, PMID_42346077, PMID_42394452, PMID_42118128, 720aed3e, PMID_42079331, PMID_42272466, a698e5fc, fa6f7211, NCT03838549, NCT05216068

#### Generated Answer

> Here are the claims and metrics related to pre-implantation genetic diagnosis:

* High risk men's perceptions of pre-implantation genetic diagnosis for hereditary breast and ovarian cancer [PubMed PMID_20713415]
* Factors associated with preimplantation genetic diagnosis acceptance among women concerned about hereditary breast and ovarian cancer [NCCN f783eeb2] [NCCN 623b8e28] [NCCN 2ad42c69]
* Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth [PubMed PMID_18302307]
* Preimplantation genetic diagnosis for BRCA1/2--a novel clinical experience [PubMed PMID_19248143]
* Conflict between values and technology: perceptions of preimplantation genetic diagnosis among women at increased risk for hereditary breast and ovarian cancer [PubMed PMID_19554475]
* Ten-year single-centre experience in families at risk of hemophilia using preimplantation genetic testing for monogenic diseases (PGT-M) [PubMed PMID_42415645]
* 19 couples underwent multidisciplinary counselling and pre-clinical PGT work-up [PubMed PMID_42415645]
* 69 embryos were biopsied and genetically characterized [PubMed PMID_42415645]
* 58 embryos had a conclusive diagnosis (84%) [PubMed PMID_42415645]
* 26 unaffected embryos suitable for transfer, resulting in 13 pregnancies (50% implantation rate per transfer), leading to eight live births, four miscarriages and one therapeutic termination [PubMed PMID_42415645]

Please note that these claims and metrics are extracted from the provided context blocks.

---

### q_synth_48: What percentage of males with breast cancer who were not selected based on family history test positive for a germline BRCA2 mutation?

**Expected ID:** `581178bb` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_trials ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 842b0a2d, eb2fadf4, 4d9a44aa, 83fc9abd, PMID_42464142, NCT07253051, 35001f4b, 7394e999, 9bde9635, NCT04499534, c69ed016, 2fa830c9, db70acab, 95b0b10c, 2dadab8f, 4cbc1020, 24830cf3, dd1f389e, PMID_42127212, PMID_42471715, PMID_41731704, NCT04613440, PMID_42446852, NCT03495609, PMID_41823437, NCT04428736, PMID_42433303, PMID_42457876

#### Generated Answer

> Based on the provided context, the following claims and metrics are extracted:

* The prevalence of pathogenic BRCA1/BRCA2 variants was 14.35% in Vietnamese patients diagnosed with breast, ovarian, prostate, or pancreatic cancer [PubMed PMID_42464142]
* The mutation burden was highest in ovarian cancer and triple-negative breast cancer (TNBC), where BRCA1 variants predominated over BRCA2 [PubMed PMID_42464142]
* Several BRCA1 truncating variants and recurrent BRCA2 loss-of-function variants were enriched in TNBC, with additional cases observed in ovarian, prostate, and pancreatic cancers [PubMed PMID_42464142]

Note that these claims and metrics are specific to the Vietnamese population and may not be generalizable to other populations.

---

### q_synth_49: What changes were made to the genetic testing recommendation for family members without known familial mutations of PTEN?

**Expected ID:** `5ea94a99` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT03680924, NCT02991807, 148802fb, NCT05630105, de87be0c, 6fa211a3, c17d76bb, 28b6b6a3, ff346276, 30f0a973, NCT06080165, f5dd5c5a, NCT05111080, 0ec096c0, fe677e86, PMID_41527390, 97fc614f, c05478df, 3b1162e7, PMID_41817392, 42426480, 092b087c, PMID_42359636, PMID_41953055, PMID_42009253, PMID_41730753, PMID_42199066, PMID_42035472

#### Generated Answer

> Based on the provided context blocks, here are some claims and metrics related to PTEN:

* Phosphatase and TENsin homolog (PTEN) gene germline mutations are associated with a spectrum of clinical manifestations characterized by neurocognitive deficits, intellectual disability, autism symptomatology, skin lesions, macrocephaly, hamartomatous overgrowth of tissues, and an increased risk of cancers [ClinicalTrials.gov NCT02991807]
* Comprehensive genetic testing should include full sequence analysis, deletion/duplication analyses, and promoter analysis for a PTEN mutation [NCCN 148802fb]
* Consider comprehensive PTEN testing of patient or, if unaffected, test family member with highest likelihood of a mutation [NCCN de87be0c]

---

### q_synth_50: When should premenopausal women perform breast self-exam training for optimal awareness?

**Expected ID:** `cb944d38` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT07562321, NCT06777745, aeb2acb1, fb2277b7, 718cbc76, aa7b23d7, PMID_40386171, NCT07692464, NCT05418985, d5ce4638, 73b42022, ef43315b, 017f67d3, 70a3b1fb, PMID_42002553, 2bd272cb, b2819ddd, f6e4f604, PMID_41997232, acb26708, ab1a609f, 77c056a4, NCT05995483, PMID_41563932, PMID_40361232, PMID_41299545

#### Generated Answer

> Here are some key points related to breast self-exam training:

* Prior to testing, women at risk for breast cancer should start training and education in breast self-examination at 18 years of age [NCCN aa7b23d7].
* Members of families with LFS should undergo training in breast self-examination with regular monthly practice starting at 35 years of age [NCCN fb2277b7].
* The American College of Surgeons recommends that women perform regular self-breast exams on a monthly basis, starting at age 18 [NCCN aeb2acb1].

Additionally, there are several studies and trials mentioned in the provided context blocks that relate to breast self-exam training:

* A randomized controlled trial (RCT) is recruiting participants to evaluate the effect of an AI-supported flipped learning model on nursing students' breast self-examination knowledge and performance [ClinicalTrials.gov NCT07562321].
* Another RCT, "Improvement of Breast Examination Skills of Midwifery Students: Model Supported Education Study", aims to improve breast examination skills of midwifery students using a model-supported education approach [ClinicalTrials.gov NCT06777745].

---

